English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
UDIBI
Mycobacterium tuberculosis Catalase Inhibits the Formation of Mast Cell Extracellular Traps. SHOW MORE
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). SHOW MORE
-
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. SHOW MORE
-
UDIBI
Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. SHOW MORE
-
UDIBI
Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine. SHOW MORE
-
UDIBI
Published: September 20, 2019 Utilization of naproxen by Amycolatopsis sp. Poz 14 and detectionof the enzymes involved in the...
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
